Asciminib is one of the six tyrosine kinase inhibitor (TKI) drugs used for CML, a class that began with the introduction of ...

With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia ...

Olverembatinib, developed by Ascentage Pharma, will be added to China’s National Reimbursement Drug List (NRDL) starting next ...

(RTTNews) - HUTCHMED (China) Limited (?HCM) announced that following the contract renewal with the China National Healthcare Security Administration ("NHSA"), the updated National Reimbursement Drug ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal ...

ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...

The oral solution offers precise dosing, benefiting patients with swallowing difficulties or requiring tailored dosing.

An expert highlighted unmet needs in treating T-cell acute lymphoblastic leukemia and where research may focus in the future.

In this randomized controlled trial, among adults diagnosed with chronic myeloid leukemia (CML), asciminib demonstrated a ...